The material of the investor webcast presentation and conference call upon request of the Offer
Information upon request of the Offer on the material of the investor webcast presentation and conference call in relation with the voluntary public purchase offer, disclosed earlier today.
Egis Pharmaceuticals PLC (Egis) announces that besides having received today a voluntary public purchase offer (Offer) from Arts et Techniques du Progrès (Offeror), a wholly owned subsidiary of Servier Group (Servier), Egis also received from the Offer and hereby publishes upon request of the Offeror the attached material of the investor webcast presentation and conference call held by Offeror at 3pm CET today.
Egis’s website uses cookies to run our website, improve the user experience and monitor the activities. You can customize the use of the cookies by adapting the settings.
Cookies necessary for basic functioning
These cookies ensure the appropriate functioning of the website, facilitate its use and collect information on its use without identifying visitors.
Functional cookies
In order to enhance the user experience, we use cookies which record the use of certain functions of the website, thus enabling users to have the same settings at the time of their next visit.
Cookies for statistical purposes
They provide statistical data on the performance of the website (such as number of page loads, average time spent on the website) in order to collect data for the operator of the website on the website usage patterns of users. These cookies do not identify visitors, information collected by them relate to the number of subpages visited by the user, the length of each session, the types of error messages, etc. Cookies for statistical purposes are automatically placed on the user’s devices during browsing, and you can delete such cookies in the browser settings.
Egis’ website uses cookies to run our website, improve the user experience and monitor the activities. You can customize the use of the cookies by adapting the settings.